IRIDEX Corporation (IRIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IRIDEX Corporation (IRIX) has a cash flow conversion efficiency ratio of 0.120x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($589.00K) by net assets ($4.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of IRIDEX Corporation to measure how much of total assets are equity-financed.
IRIDEX Corporation - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how IRIDEX Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is IRIDEX Corporation's earnings quality to evaluate the quality of earnings relative to operating cash generation.
IRIDEX Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IRIDEX Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BALAXI PHARMACEUTICALS LIMITED
NSE:BALAXI
|
0.063x |
|
Cowell Development Tbk
JK:COWL
|
0.138x |
|
HENGYANG PETROCHEM (5HY.SG)
STU:5HY
|
-0.002x |
|
MDJM Ltd
NASDAQ:UOKA
|
-0.154x |
|
Dome Gold Mines Ltd
AU:DME
|
-0.023x |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
-0.084x |
|
Managepay Systems Bhd
KLSE:0156
|
-0.040x |
|
Spirent Communications plc
LSE:SPT
|
0.039x |
Annual Cash Flow Conversion Efficiency for IRIDEX Corporation (1995–2025)
The table below shows the annual cash flow conversion efficiency of IRIDEX Corporation from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see IRIX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.92 Million | $-2.12 Million | -0.430x | +87.63% |
| 2024-12-31 | $2.10 Million | $-7.29 Million | -3.474x | -390.43% |
| 2023-12-31 | $9.52 Million | $-6.75 Million | -0.708x | -28.23% |
| 2022-12-31 | $17.23 Million | $-9.52 Million | -0.552x | -256.64% |
| 2021-12-31 | $23.30 Million | $8.22 Million | 0.353x | +289.21% |
| 2020-12-31 | $17.37 Million | $-3.24 Million | -0.186x | +46.52% |
| 2019-12-31 | $22.70 Million | $-7.91 Million | -0.349x | -4.16% |
| 2018-12-31 | $29.96 Million | $-10.03 Million | -0.335x | -186.47% |
| 2017-12-31 | $30.52 Million | $-3.56 Million | -0.117x | -3076.34% |
| 2016-12-31 | $39.16 Million | $-144.00K | -0.004x | +79.11% |
| 2015-12-31 | $33.69 Million | $-593.00K | -0.018x | -114.79% |
| 2014-12-31 | $33.74 Million | $4.01 Million | 0.119x | +301.07% |
| 2013-12-31 | $25.85 Million | $767.00K | 0.030x | +246.69% |
| 2012-12-31 | $21.91 Million | $-443.00K | -0.020x | -114.88% |
| 2011-12-31 | $22.43 Million | $3.05 Million | 0.136x | -24.10% |
| 2010-12-31 | $19.43 Million | $3.48 Million | 0.179x | -60.42% |
| 2009-12-31 | $15.03 Million | $6.80 Million | 0.452x | +5635.50% |
| 2008-12-31 | $11.75 Million | $-96.00K | -0.008x | +70.55% |
| 2007-12-31 | $18.81 Million | $-522.00K | -0.028x | +35.57% |
| 2006-12-31 | $32.16 Million | $-1.39 Million | -0.043x | -153.67% |
| 2005-12-31 | $34.52 Million | $2.77 Million | 0.080x | +230.82% |
| 2004-12-31 | $31.78 Million | $771.00K | 0.024x | -85.34% |
| 2003-12-31 | $30.83 Million | $5.10 Million | 0.165x | +98.40% |
| 2002-12-31 | $30.20 Million | $2.52 Million | 0.083x | +168.46% |
| 2001-12-31 | $29.83 Million | $-3.63 Million | -0.122x | -4921.99% |
| 2000-12-31 | $30.50 Million | $-74.00K | -0.002x | -102.33% |
| 1999-12-31 | $27.50 Million | $2.86 Million | 0.104x | +234.75% |
| 1998-12-31 | $25.90 Million | $-2.00 Million | -0.077x | -1745.56% |
| 1997-12-31 | $23.90 Million | $-100.00K | -0.004x | +93.08% |
| 1996-12-31 | $21.50 Million | $-1.30 Million | -0.060x | -131.58% |
| 1995-12-31 | $4.70 Million | $900.00K | 0.191x | -- |
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and Oc… Read more